Gerresheimer AG
XETRA:GXI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (1.7), the stock would be worth €38.68 (60% upside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.1 | €24.18 |
0%
|
| 3-Year Average | 1.7 | €38.68 |
+60%
|
| 5-Year Average | 1.8 | €41.24 |
+71%
|
| Industry Average | 1.7 | €38.45 |
+59%
|
| Country Average | 1.3 | €30.78 |
+27%
|
Forward EV/S
Today’s price vs future revenue
| Today's Enterprise Value | Revenue | Forward EV/S | ||
|---|---|---|---|---|
|
€2.2B
|
/ |
Sep 2025
€2.3B
|
= |
|
|
€2.2B
|
/ |
Dec 2025
€2.3B
|
= |
|
|
€2.2B
|
/ |
Dec 2026
€2.4B
|
= |
|
|
€2.2B
|
/ |
Dec 2027
€2.5B
|
= |
|
|
€2.2B
|
/ |
Nov 2028
€2.8B
|
= |
|
|
€2.2B
|
/ |
Nov 2029
€2.9B
|
= |
|
|
€2.2B
|
/ |
Nov 2030
€3B
|
= |
|
|
€2.2B
|
/ |
Nov 2031
€3.5B
|
= |
|
|
€2.2B
|
/ |
Nov 2032
€3.6B
|
= |
|
Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| DE |
|
Gerresheimer AG
XETRA:GXI
|
835.2m EUR | 1.1 | 35.8 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
936.1B USD | 328.4 | 3 881 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
173.3B USD | 4.7 | 25.7 | |
| US |
|
Danaher Corp
NYSE:DHR
|
126.5B USD | 5.6 | 34.4 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 17.9 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
331.7B CNY | 6.3 | 16.8 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
32.5B CHF | 5.5 | -119.8 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
31.5B USD | 4.8 | 25 | |
| US |
|
Waters Corp
NYSE:WAT
|
28.7B USD | 9.6 | 46.7 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
26.6B USD | 2.4 | 19.8 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
25.2B USD | 6.9 | 29.7 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.7 |
| Median | 1.3 |
| 70th Percentile | 2.5 |
| Max | 21 171.2 |
Other Multiples
Gerresheimer AG
Glance View
Gerresheimer AG, nestled in the heart of Germany, has evolved into a cornerstone of the pharmaceutical and healthcare industries. Its beginnings were humble, rooted in glass manufacturing over a century ago, but the company has since metamorphosed into a leading provider of specialized products for the global healthcare market. Today, Gerresheimer's portfolio stretches well beyond glass, encompassing a range of highly technical and innovative products. The company specializes in producing glass and plastic containers, including vials, ampoules, and cartridges, which are crucial for delivering drugs and vaccines safely to patients worldwide. Its sophisticated offerings extend to complex drug delivery devices like insulin pens and inhalers, showcasing its deep integration into the supply chains of major pharmaceutical companies. Gerresheimer's business model thrives on close partnerships with these pharmaceutical giants, crafting tailor-made solutions for diverse therapeutic areas. This strategic alignment positions it well amid growing global health needs and an aging population, driving steady demand for its high-margin products. Its operations are bolstered by an international footprint of production facilities, allowing for high-quality, efficient manufacturing and distribution. This network not only enhances its logistics but also supports the company's commitment to innovation, enabling it to meet specific regulatory and market requirements across different regions. Ultimately, Gerresheimer AG makes its mark and profits through a combination of cutting-edge technology, stringent quality standards, and strategic relationships, securing its place as a vital player in the global healthcare ecosystem.